Scinai Immunotherapeutics (SCNI) Revenue (2024 - 2026)

Scinai Immunotherapeutics has disclosed Revenue across 3 years of filings, most recently posting $460000.0 for Q2 2026.

• In Q2 2026, Revenue rose 145.99% year-over-year to $460000.0; the TTM figure through Jun 2026 stood at $1.7 million (up 50.13% YoY), while the FY2025 annual figure was $2.4 million, up 263.07% from the prior year.
• Revenue came in at $460000.0 for Q2 2026 at Scinai Immunotherapeutics, down from $489000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $586000.0 in Q1 2025 to a low of $168000.0 in Q3 2024.
• Average Revenue over 3 years is $349333.3, with a median of $333000.0 recorded in 2024.
• The largest YoY upside for Revenue was 145.99% in 2026 against a maximum downside of 16.55% in 2026.
• Over 3 years, Revenue stood at $206000.0 in 2024, then retreated by 9.22% to $187000.0 in 2025, then surged by 145.99% to $460000.0 in 2026.
• Per Business Quant data, the three most recent Revenue figures were $460000.0 in Q2 2026, $489000.0 in Q1 2026, and $187000.0 in Q2 2025.